Hilleman CEO Davinder Gill is leaving the global vaccine R&D organization after eight years at the helm and several mileposts. Incoming CEO Raman Rao takes charge from 1 February.
Hilleman Laboratories’ long-serving CEO, Davinder Gill, is moving on after an eventful stint at the helm and will hand over the reins to former Takeda Pharmaceutical Co. Ltd. executive Raman Rao.
Gill, who has been Hilleman’s CEO since 2012, has steered the global vaccine R&D organization to some important milestones including the licensing last year of its oral cholera vaccine, Hillchol, to Bharat Biotech International Ltd
CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.
As CEO Anderson backs high prices for innovative drugs in Europe
Novo Nordisk enjoyed a surprise GLP-1 agonist contracting win in the first quarter of 2025. This provided a welcome boost to its stock after it had spent the previous quarter on the back foot against rival Lilly.
The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.
The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.
Helped by a recent major platform deal with GSK, South Korea's ABL Bio is aiming to build its R&D portfolio with an eye on being acquired in the future. CEO Sang Hoon Lee sat down with Scrip to explain the venture's journey so far and its ambitious roadmap.
Roche/Genentech unveiled plans for a $700m-plus manufacturing facility for weight loss drugs in North Carolina as President Trump signaled such investments could mean no tariffs for pharma.
